854 related articles for article (PubMed ID: 27773786)
1. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
[TBL] [Abstract][Full Text] [Related]
2. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
4. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
5. Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy.
Oprescu B; Raduna O; Mihaicuta S; Frent S
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541113
[No Abstract] [Full Text] [Related]
6. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.
Siva R; Green RH; Brightling CE; Shelley M; Hargadon B; McKenna S; Monteiro W; Berry M; Parker D; Wardlaw AJ; Pavord ID
Eur Respir J; 2007 May; 29(5):906-13. PubMed ID: 17301099
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
8. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
9. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
10. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
Barnes PJ
J Allergy Clin Immunol; 2015 Sep; 136(3):531-45. PubMed ID: 26343937
[TBL] [Abstract][Full Text] [Related]
11. Agents against cytokine synthesis or receptors.
Yamagata T; Ichinose M
Eur J Pharmacol; 2006 Mar; 533(1-3):289-301. PubMed ID: 16457805
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease.
Mkorombindo T; Dransfield MT
Int J Chron Obstruct Pulmon Dis; 2019; 14():1779-1787. PubMed ID: 31496677
[TBL] [Abstract][Full Text] [Related]
13. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
14. Targeting IL-5 in COPD.
Narendra DK; Hanania NA
Int J Chron Obstruct Pulmon Dis; 2019; 14():1045-1051. PubMed ID: 31190789
[TBL] [Abstract][Full Text] [Related]
15. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
[TBL] [Abstract][Full Text] [Related]
16. Update on new biologics for intractable eosinophilic asthma: impact of reslizumab.
Sahota J; Robinson DS
Drug Des Devel Ther; 2018; 12():1173-1181. PubMed ID: 29780238
[TBL] [Abstract][Full Text] [Related]
17. Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.
Gerday S; Graff S; Moermans C; Guissard F; Paulus V; Henket M; Louis R; Schleich F
Thorax; 2023 Nov; 78(11):1138-1141. PubMed ID: 37657926
[TBL] [Abstract][Full Text] [Related]
18. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
Bel EH; Ten Brinke A
Chest; 2017 Dec; 152(6):1276-1282. PubMed ID: 28583618
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
20. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease.
Tashkin DP; Wechsler ME
Int J Chron Obstruct Pulmon Dis; 2018; 13():335-349. PubMed ID: 29403271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]